CRIN.DE
UniCredit S.p.A.
XETRAEUREQUITY
Financial Services
DELAYED
Last price
82.70
▼ 0.18 (0.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
82.88
Day high
83.45
Day low
82.70
Volume
2.90K
Market cap
$123.91B
P/E (TTM)
11.73
52W range
57.66 – 85.96
Trailing performance
Returnvs SPY
1W
-3.03%
-1.7%
1M
+4.34%
+0.6%
3M
+12.93%
+9.8%
6M
+12.15%
+1.1%
YTD
+16.45%
+4.2%
1Y
+19.47%
-0.5%
3Y
+266.17%
+192.0%
5Y
+670.02%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRIN.DE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$123.91B
Enterprise value$179.12B
Revenue (TTM)$24.84B
Gross profit$24.84B
EBITDA—
Net income$10.73B
EPS (TTM)$7.05
Free cash flow—
Total cash$192.98B
Total debt$247.79B
Book value / share$47.00
Shares outstanding1.50B
Float1.50B
Short % of float—
Dividend yield3.81%
Beta (5Y)1.06
Valuation & profitability ratios
Trailing P/E11.73
Forward P/E—
PEG ratio0.96
Price / sales—
Price / book1.76
EV / revenue7.21
EV / EBITDA—
Gross margin0.00%
Operating margin68.88%
Profit margin43.97%
Return on equity15.78%
Return on assets1.23%
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $25.04B | $26.58B | $25.36B | $21.04B | -5.8% |
| Operating revenue | $25.04B | $26.58B | $25.36B | $21.04B | -5.8% |
| Selling, general & admin | $2.56B | $2.48B | $2.43B | $2.41B | +3.1% |
| Total operating expense | $11.19B | $12.05B | $12.45B | $11.87B | -7.1% |
| Pre-tax income | $13.57B | $12.86B | $11.45B | $7.29B | +5.5% |
| Tax provision | $2.59B | $3.09B | $1.92B | $819.00M | -16.1% |
| Net income | $10.91B | $9.72B | $9.51B | $6.46B | +12.3% |
| Net income to common | $10.71B | $9.47B | $9.33B | $6.38B | +13.1% |
| Basic EPS | 6.89 | 5.84 | 5.11 | 3.09 | +18.0% |
| Diluted EPS | 6.89 | 5.78 | 5.05 | 3.06 | +19.2% |
| Basic shares | 1.58B | 1.62B | 1.83B | 2.07B | -2.3% |
| Diluted shares | 1.58B | 1.64B | 1.85B | 2.09B | -3.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $53.29B | $54.32B | $72.34B | $134.24B | -1.9% |
| Property, plant & equipment | $7.34B | $7.43B | $7.76B | $8.59B | -1.2% |
| Goodwill & intangibles | $2.94B | $2.23B | $2.27B | $2.35B | +31.9% |
| Total assets | $870.24B | $784.00B | $784.97B | $857.77B | +11.0% |
| Total debt | $129.94B | $122.72B | $122.52B | $115.46B | +5.9% |
| Total liabilities | $802.13B | $721.16B | $720.73B | $794.28B | +11.2% |
| Retained earnings | $10.91B | $9.72B | $9.51B | $6.46B | +12.3% |
| Shareholder equity | $67.71B | $62.44B | $64.08B | $63.34B | +8.4% |
| Net tangible assets | $64.77B | $60.21B | $61.81B | $60.98B | +7.6% |
| Shares issued | 1.56B | 1.55B | 1.78B | 1.94B | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $10.98B | $9.77B | $9.53B | $6.47B | +12.3% |
| Depreciation & amortisation | $1.28B | $1.31B | $1.63B | $1.30B | -2.0% |
| Change in working capital | -$9.69B | -$28.17B | -$59.30B | $1.48B | +65.6% |
| Operating cash flow | $8.53B | -$7.08B | -$41.13B | $10.26B | +220.5% |
| Capital expenditure | -$1.27B | -$1.74B | -$1.15B | -$1.17B | +27.2% |
| Investing cash flow | -$4.02B | -$1.06B | -$787.00M | -$237.00M | -277.4% |
| Dividends paid | -$5.01B | -$4.95B | -$2.44B | -$1.70B | -1.2% |
| Financing cash flow | -$7.96B | -$10.99B | -$8.45B | -$5.55B | +27.6% |
| Free cash flow | $7.26B | -$8.82B | -$42.28B | $9.09B | +182.3% |
| End cash position | $38.45B | $41.44B | $61.00B | $111.78B | -7.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $6.54B | $7.07B | $5.35B | — | $6.99B | $6.55B | -7.5% |
| Operating revenue | $6.54B | $7.07B | $5.35B | — | $6.99B | $6.55B | -7.5% |
| Total operating expense | $2.34B | $2.55B | $3.77B | — | $2.55B | $2.53B | -8.5% |
| Pre-tax income | $3.95B | — | — | — | — | — | — |
| Tax provision | $981.00M | $1.03B | -$427.00M | — | $934.00M | $1.12B | -4.8% |
| Net income | $2.95B | $3.26B | $2.14B | — | $3.34B | $2.77B | -9.5% |
| Net income to common | $2.90B | $3.22B | $1.96B | — | $3.34B | $2.77B | -9.7% |
| Basic EPS | 1.94 | 2.15 | 1.22 | 1.71 | 2.16 | — | -9.8% |
| Diluted EPS | 1.94 | 2.15 | 1.22 | 1.71 | 2.16 | — | -9.8% |
| Basic shares | 1.50B | 1.50B | 1.78B | 1.54B | 1.55B | — | +0.0% |
| Diluted shares | 1.50B | 1.50B | 1.78B | 1.54B | 1.55B | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $57.89B | $48.18B | $53.29B | $53.02B | $44.00B | +20.1% |
| Property, plant & equipment | $8.60B | $8.76B | $7.34B | $8.82B | $8.80B | -1.8% |
| Goodwill & intangibles | $2.92B | $2.91B | $2.94B | $3.27B | $2.50B | +0.2% |
| Total assets | $932.09B | $902.16B | $870.24B | $860.33B | $795.90B | +3.3% |
| Total debt | $142.52B | — | — | $128.37B | — | — |
| Total liabilities | $861.27B | $833.36B | $802.13B | $791.91B | $730.10B | +3.3% |
| Retained earnings | $6.12B | $3.22B | $10.91B | $6.12B | $2.80B | +90.3% |
| Shareholder equity | $70.42B | $68.42B | $67.71B | $68.02B | $65.40B | +2.9% |
| Net tangible assets | $67.51B | $65.51B | $64.77B | $64.75B | $62.90B | +3.0% |
| Shares issued | 1.51B | 1.51B | 1.56B | 1.56B | 1.55B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $6.48B | +5.1% |
| Next quarter | — | — | $6.49B | +14.1% |
| Current year | — | — | $26.32B | +7.3% |
| Next year | — | — | $27.66B | +5.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions55.30%
Institutions holding754
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
84.20
-1.78% from price
SMA 20
83.68
-1.17% from price
SMA 50
81.53
+1.43% from price
SMA 100
75.63
+9.34% from price
SMA 200
72.03
+14.81% from price
EMA 12
83.68
-1.17% from price
EMA 26
83.01
-0.37% from price
EMA 50
80.98
+2.12% from price
RSI (14)
48.9
Neutral
MACD (12,26,9)
0.67
Hist -0.44
ATR (14)
1.12
1.36% of price
Realised vol 30D
23.1%
Annualised
Bollinger upper
87.04
20, 2σ
Bollinger lower
80.31
20, 2σ
50 / 200 cross
Golden
81.53 vs 72.03
Trend bias
Above 200
+14.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.40
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
23.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-24.1%
Peak to trough
Max drawdown 5Y
-49.3%
Peak to trough
ATR 14
1.12
1.36% of price
Beta (reported)
1.06
5Y monthly, from filing
Dividends & splits
Forward rate$3.15 / yr
Forward yield3.81%
5-year avg yield5.02%
Payout ratio44.64%
Ex-dividend dateApr 20, 2026
Next pay date—
Last split1:10
Split dateJan 23, 2017
Headlines
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 12m ago
TME Pharma provides update on its activities
GlobeNewswire · 12m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 17m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 17m ago
Board Update
GlobeNewswire · 17m ago
Aegon implements EUR 150 million increase in share buyback program
GlobeNewswire · 17m ago
TOMY's "TOMICA XROSS RESCUE" Diorama-based Short Animation Series to Begin Streaming Aug. 26, 2026
PR Newswire · 17m ago
Holding(s) in Company
GlobeNewswire · 17m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.